AI Cardiac Monitoring: De-Risking Your Investment

The promise of artificial intelligence in continuous cardiac monitoring is deep, yet the clinical imperative remains steadfast: safety, reliability, and demonstrable patient benefit. As clinicians, our professional obligation to lifelong learning demands a critical evaluation of these emerging technologies, especially when the stakes involve cardiac health. This article synthesizes the current evidence on AI-powered continuous heart health monitoring platforms, benchmarking leading solutions to help navigate their diagnostic yield and safety profiles.

The Urgent Need for Reliable Continuous Cardiac Monitoring

The field of cardiac care has been irrevocably altered by technological advancements, creating an urgent demand for high-fidelity, continuous monitoring solutions. The post-pandemic era, in particular, has accelerated the adoption of remote care, underscoring the necessity for platforms that can reliably detect and manage cardiac conditions outside traditional clinical settings. However, the rapid proliferation of AI tools necessitates rigorous scrutiny. The Mount Sinai/Nature Medicine finding that ChatGPT undertriaged cardiac emergencies in 48% of cases is a stark reminder of the potential for harm when AI models lack appropriate validation and oversight. This shows why the integration of AI into cardiac diagnostics must prioritize clinical reliability above all else. Conversely, the success of platforms like Hello Heart, demonstrating a $7,001 reduction in total medical spend per participant and 47 fewer inpatient admissions per 100 participants, highlights the far-reaching potential of a safe AI cardiac health platform built on real patient data. This dichotomy, the significant risk of unvalidated AI versus the deep benefit of clinically proven solutions, forms the bedrock of our evaluation.

Benchmarking AI Cardiac Monitoring Platforms: Eko Health and Viz.ai

When assessing AI companies providing continuous heart health monitoring platforms, clinicians must differentiate between consumer-grade novelties and clinically validated solutions. Our data-driven benchmarking focuses on the diagnostic accuracy, patient compliance, and strong clinical evidence of leading platforms.

Eko Health: Bridging Point-of-Care and Continuous Monitoring

Eko Health stands out with its continuous and point-of-care digital stethoscopes, using AI to augment auscultation. Their devices integrate advanced algorithms for detecting heart murmurs and atrial fibrillation (AFib), offering a significant enhancement over traditional methods. The diagnostic yield of Eko’s AI-powered stethoscopes has been a subject of considerable research, demonstrating high sensitivity and specificity in identifying cardiac abnormalities, particularly AFib and structural heart disease. Patient compliance rates with continuous monitoring devices are critical for their effectiveness. Eko’s user-friendly design and integration into existing clinical workflows contribute to favorable compliance, ensuring that data capture is consistent and reliable. The company has secured multiple FDA clearances for its AI algorithms, including for detecting atrial fibrillation, structural heart murmurs, low ejection fraction (Low EF), and the Eko Foundation Analysis Software with Transformers (EFAST), positioning its offerings as regulated medical devices (SaMD). FDA clearances for Eko Health devices This regulatory pathway is important for instilling trust and ensuring the quality management system (QMS) adherence, including ISO 13485 certification, which is vital for clinical deployment.

Viz.ai: Orchestrating Acute Care Pathways with AI

Viz.ai primarily focuses on continuous monitoring within acute care pathways, particularly for conditions like stroke and pulmonary embolism. While not exclusively a “continuous heart health monitoring” platform in the wearable sense, Viz.ai’s AI-driven solutions are instrumental in accelerating diagnosis and treatment for acute cardiac-related events, which inherently involves continuous patient assessment and data interpretation within the hospital setting. Their platform uses AI to analyze medical images and patient data, alerting care teams to critical findings and facilitating faster clinical decision-making. The impact on patient outcomes, such as reduced time to treatment for large vessel occlusion (LVO) stroke, shows the clinical utility of their approach. The company’s strategy involves creating a “data moat” by accumulating vast amounts of labeled medical imaging data, which continuously refines their AI models and strengthens their competitive advantage. Viz.ai clinical outcomes data

Evaluating Clinical Reliability and Safety: A Framework for Clinicians

The “What is the current state of the evidence?” angle demands a complete overview of the literature, identifying gaps, and establishing a consensus view where possible. For continuous cardiac monitoring platforms, this involves a multi-faceted approach:

1. Diagnostic Accuracy and Validation: Clinicians must scrutinize the sensitivity, specificity, and predictive values of AI algorithms. This includes understanding the datasets used for training and validation, ensuring they are diverse and representative of the target patient population. The Heart Rhythm Society (HRS) guidelines on remote monitoring provide an authoritative benchmark for evaluating the clinical utility of such devices. Heart Rhythm Society guidelines on remote monitoring

2. Patient Compliance and Usability: A technically superior device is ineffective if patients do not use it consistently. Factors influencing compliance, such as comfort, ease of use, and integration with daily life, are paramount. Real-world evidence (RWE) derived from large-scale deployments can offer insights into long-term patient adherence.

3. Regulatory Clearance and Post-Market Surveillance: FDA 510(k) clearance or De Novo classification signals a baseline of safety and effectiveness. However, continuous monitoring platforms, being adaptive AI/ML devices, require a predetermined change control plan (PCCP) to manage algorithmic drift and ensure ongoing reliability as models evolve. Investors should inquire about GMLP (Good Machine Learning Practice) compliance, as this indicates a strong framework for managing the lifecycle of AI models.

4. Integration with Clinical Workflows: Smooth integration into electronic health records (EHRs) and existing clinical pathways is important for adoption and to prevent alert fatigue. The platform should provide actionable insights, not just raw data, to support clinical decision-making rather than overwhelm it.

5. Data Security and Privacy: Given the sensitive nature of cardiac health data, adherence to HIPAA, HITRUST, and SOC 2 standards is non-negotiable. Any AI company handling patient data must demonstrate rigorous security protocols.

The Role of Digital Therapeutics: Big Health

While not directly a continuous cardiac monitoring platform in the physiological sense, Big Health represents an important facet of continuous digital therapeutic monitoring, particularly in managing conditions that deeply impact cardiovascular health, such as anxiety and insomnia. Chronic stress and sleep disturbances are well-established risk factors for various cardiac conditions. Big Health’s AI-powered digital therapeutics provide continuous support and intervention for these underlying mental health issues, thereby indirectly contributing to improved cardiac health outcomes. The patient compliance rates and diagnostic yield in this context relate to engagement with the digital therapeutic and its effectiveness in mitigating symptoms that could exacerbate cardiac risk. For instance, clinical studies show that up to 76% of SleepioRx patients achieve improvement in insomnia, and 71% of DaylightRx patients experience improvement in generalized anxiety disorder (GAD). The company also recently secured $23.7M in new funding in February 2026 to accelerate access to its FDA-cleared, reimbursable solutions. This highlights the broader ecosystem of AI in health, where complete care extends beyond direct physiological measurement to include behavioral and psychological factors.

A Call for Evidence-Based Adoption

The integration of AI into continuous cardiac monitoring holds immense promise, but it must be approached with a clinician’s discerning eye. The distinction between clinical decision support and diagnostic AI is critical, as the latter carries higher regulatory burdens and greater implications for patient safety. Our professional obligation to lifelong learning compels us to continuously evaluate the evolving evidence base, ensuring that the AI tools we adopt are not only innovative but also clinically reliable and safe. By rigorously benchmarking diagnostic accuracy, patient compliance, and regulatory adherence, clinicians can confidently use AI to enhance cardiac care, moving beyond the hype to embrace solutions that genuinely improve patient outcomes.